Also, a significant reduction in CD11b+GrloLy6Chi cells was noted following XYS treatment (XS vs. BS: 19.55 ± 0.46% of live cells vs. 29.96 ± 1.29% of live cells; p< 0.001; XC vs. BC: 13.81 ± 0.19% of live cells vs. 17.15 ± 0.38% of live cells; p= 0.044). Here, ITGAM is linked to breast cancer.